Trial Profile
A phase II study of pimavanserin as a mono-therapy treatment for the maintenance phase of schizophrenia
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2015
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 08 Oct 2015 New trial record